The Commission has been established by the WHO to look at ways of stimulating the development of new medicines to combat diseases that affect the developing world, and a total of ten names from around the world has been announced. Prof. Jones is the only British-based member.
"The pharmaceutical industry has been at the forefront of developing truly effective medicines and partnerships to bring sustainable programmes for the healthcare of people in the developing world," said Prof. Jones.
"I see this as an exciting opportunity to build on what we have been doing for many years and to find pragmatic solutions to the human tragedy of ill-health in developing nations. It is up to me and the other members of the commission to find some real answers that can truly work."
The Commission is a new project led by the WHO and is intended to focus on new rather than existing medicines. As well as intellectual property rights, the Commission will look at other possible incentives for research and development.
Prof. Jones is also a member of the Medicines for Malaria Venture, a non-profit foundation created to discover, develop and deliver new affordable antimalarial drugs through effective public-private partnerships. During his time as R&D Director at Wellcome, Prof. Jones was responsible for the development of a number of medicines for the developing world, including Malarone for malaria and AZT for HIV/AIDS.
For further information, please contact: ABPI Press Office 020 7747 1410